The impact of skeletal muscle mass on survival outcome in biliary tract cancer patients

Panita Limpawattana¹, Daris Theerakulpisut², Kosin Wirasorn³, Aumkhae Sookprasert³, Narong Khuntikeo⁴, Jarin Chindaprasirt³*

¹ Division of Geriatric Medicine, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand , ² Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand , ³ Medical Oncology Unit, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand , ⁴ Division of Hepatobiliary Surgery, Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

* jarich@ku.ac.th

Abstract

Low skeletal muscle mass is frequently observed in cancer patients and is known to be a poor prognostic factor for survival outcomes. The purposes of our study were to determine the prevalence of sarcopenia and its relation to mortality in biliary tract cancer. Body composition measurements (skeletal muscle index, total fat mass, bone mineral content) were evaluated by using dual-energy x-ray absorptiometry in 75 biliary tract cancer patients before chemotherapy. Muscle strength was measured by handgrip strength and gait speed. Overall survival and its associated factors were determined. The mean appendicular muscle mass was 17.8±2.7 kg in men and 14.0±2.1 kg in women (p < 0.05). Sarcopenia was diagnosed in 46 patients (61.3%) and higher proportion of men was classified as sarcopenia than women (69.0% vs 35.3%, p < 0.05). Multivariable analysis adjusted for chemotherapy regimen and age revealed that high appendicular muscle mass independently predicted better survival outcomes (HR 0.40; 95% CI, 0.18 to 0.88; p = 0.023). Sarcopenia is common in biliary tract cancer patients and low appendicular muscle mass was associated with poor survival outcome.

Introduction

Biliary tract cancer is common in Thailand, but the prevalence is increasing worldwide [1, 2]. Even though there is a screening program, most of the tumors detected are in advanced stage [3]. Most BTC patients are not eligible for curative resection resulting in a dismal prognosis, with a median survival of 8–12 months despite palliative chemotherapy [4]. The pooled analysis of two randomized phase III trials showed the superior survival with cisplatin-gemcitabine group with a median survival of 11.6 months compared with 8.0 months in gemcitabine alone group [5]. However, the response rate was only 19% in the bile duct tumor subgroup and there
were nearly 70% of patients suffered from grade 3 or 4 adverse events [6]. Unquestionably, we have restricted access to predict who will get the largest survival benefit prior to the treatment. Although tumor biology is a vital part determining the treatment outcome, patient factors also play a major role. Even though ECOG performance status is widely used to assess the suitability for combination chemotherapy, it is subjective to assessors and there was a high inter-observer variability [7, 8].

Low muscle mass and poor physical function or sarcopenia is classified according to definitions based on the appendicular muscle mass, which is measured by dual x-ray absorptiometry (DXA) scan [9]. Wasting of skeletal muscle has been shown to be associated with increased chemotherapy and targeted drugs adverse events, postoperative complications, and as a predictor of poor survival [10–13]. These findings suggest that low muscle mass may be an objective measure of the tolerability of treatment and should be considered in treatment planning and decision-making regarding fitness for combination chemotherapy.

Accordingly, the objective of the current study was to describe the prevalence of sarcopenia among BTC patients and to investigate its impact on mortality.

Materials and methods

This single-center, prospective study included patients with BTC undergoing first-line chemotherapy with fluoropyrimidine or gemcitabine-based regimen from January 2016 to September 2017 in Srinagarind Hospital, Khon Kaen University. Inclusion criteria were age of at least 18 years old, histological or cytological proven biliary tract cancer, ECOG performance status of 0–1, and adequate organ function. Patients were excluded if they had a second malignancy, had other active medical illnesses, were unable to undergo the dual-energy X-ray absorptiometry (DXA), or had conditions that would affect the DXA results. Gemcitabine was administered weekly with either cisplatin or carboplatin as physician’s choice (8 cycles of 1000 mg/m$^2$ day 1, 8 per 3 weeks) i.e., a total of 24 weeks. Another regimen was platinum combined with 5-fluorouracil 1000 mg/m$^2$ every 3 weeks i.e., a total of 24 weeks. This study was approved by the Khon Kaen University Ethics Committee as instituted by the Declaration of Helsinki (Number HE581333). Written informed consents were obtained from all patients.

Body composition and function measurements

Body composition measurement was performed before chemotherapy and consisted of the measurement of muscle, fat, and bone mass by Dual-energy x-ray absorptiometry (DXA). Appendicular muscle is the sum of muscle mass of upper and lower extremities. Appendicular muscle corrected for height, resulting in an appendicular muscle index (ASMI) in kg/m$^2$. Physical performance was evaluated by the 6-min walk distance. Handgrip strength was measured by a handheld dynamometer (GRIP-D (T.K.K.5401) model). Patient was in an upright position and held the dynamometer in a dominant hand with the instrument held down at the side of the body and the arm is fully extended.

Sarcopenia diagnosis is based on the criteria of the Asian Working Groups of sarcopenia (AWGs) consisting of low muscle mass and low muscle strength. The cutoff values for sarcopenia were; ASMI of $\leq 7.0$ kg/m$^2$ for men and $\leq 5.4$ kg/m$^2$ for women, and either a gait speed of $<0.8$ m/s or handgrip strength of $<26$ kg for men and $<18$ kg for women [9].

Statistical analysis

Baseline clinical characteristics were analyzed using descriptive statistics. Percentages were used to describe categorical variables. Continuous variables were described as mean ± standard deviation (SD) or as median ± interquartile range (IQR) if the data was not normally
Simple and multiple linear regression analyses were performed to identify factors contributing to appendicular muscle. The independent variables with a p-value < 0.20 or clinical significance in literature review were then entered a multiple linear regression model. Multicollinearity was checked by calculating variance inflation factors.

Overall survival (OS) was defined as the time from the date of diagnosis until the date of death or the end of follow-up (31st March 2018). Survival analysis was performed using Kaplan-Meier method and log-rank test. Univariable and multivariable Cox-proportional hazard model were performed to determine the factors associated with survival. A p-value of < 0.05 was considered to be statistically significant in all tests. All data analyses were carried out using STATA software (StataCorp LP, College Station, TX, USA).

**Results**

A total number of 75 biliary tract cancer patients were included, of which 35 were intrahepatic tumor and 38 were either perihilar or distal type. The median age was 57 years (range, 43–77 years); 58 patients (77.3%) were men (Table 1). In total, 20 patients (27%) received less than half of planned chemotherapy, resulting in a median of 4 cycles of chemotherapy in the entire cohort. Sixty patients (80%) were treated with platinum/5-fluorouracil while 15 patients (20%) underwent treatment with platinum/gemcitabine.

**Body composition and physical function**

The median BMI was 21.3 kg/m² (IQR: 18.9–23.7) in men and 21.8 kg/m² (IQR: 19.1–25.2) in women (Table 2). Mean fat mass was significantly higher in women (p < 0.05). There was a statistically significant difference in mean appendicular muscle between genders; the mean appendicular muscle in men was 17.8 ± 2.7 kg and 14.0 ± 2.1 kg in women (p < 0.05). Sarcopenia was diagnosed in 46 patients (61.3%) and higher proportion of men than women were classified as sarcopenia (69.0% vs 35.3%, p < 0.05). Regarding the physical function, the median

| Characteristics               | n = 75 |
|------------------------------|--------|
| Age (years)                  |        |
| Median (IQR)                 | 57     |
| Range                        | 43–77  |
| Male sex                     | 58 (77.3) |
| ECOG-PS                      |        |
| 0                            | 40 (53.3) |
| 1                            | 35 (46.7) |
| Location of primary tumor    |        |
| Intrahepatic                 | 35 (47.9) |
| Extrahepatic                 | 38 (52.1) |
| TNM stage II/III/IV          | 6/5/64 |
| Node-positive                | 50 (66.7) |
| Metastasis                   | 45 (60) |
| Liver surgery                | 26 (34.7) |
| Biliary drainage             | 15 (20) |
| Chemotherapy regimen         |        |
| Fluorouracil-based           | 60 (80) |
| Gemcitabine-based            | 15 (20) |

https://doi.org/10.1371/journal.pone.0204985.t001
handgrip strength was 17.9 kg in men and 15.6 kg in women without statistical significance (p = 0.14). The gait speed was indifferent between both sexes (p = 0.67).

**Association between clinical factors and appendicular muscle mass**

Low appendicular muscle mass was observed in female gender, sarcopenia, patients with metastasis, and biliary drainage (Fig 1). Female patients had significantly lower appendicular mass than male patients (p < 0.001). Patients with sarcopenia also had lower muscle mass (p < 0.05). There was no statistical association between primary tumor location or response to chemotherapy and appendicular muscle.

There was a positive linear association between hemoglobin level and appendicular muscle mass (β = 0.48, p = 0.016, Fig 2a). And there was also a statistically significant linear association between appendicular muscle mass and handgrip strength (β = 0.13, p < 0.001, Fig 2b). Advanced age was associated with decreased appendicular mass; for each one-year increase in age, there is a decrease in muscle mass of 110 g. A multiple regression was performed to predict appendicular muscle mass from gender, age, BMI, hemoglobin level, and handgrip strength. Only three variables (age, female gender, and BMI) significantly predicted appendicular muscle mass, with $R^2 = 0.569$ (Table 3). No severe collinearity between variables was detected with variation inflation factors between 1.1 and 1.3.

**Effect of appendicular muscle mass on survival**

At the follow-up time, 52 patients (69.3%) had died. The median survival of the entire cohort was 13.2 months (95% CI 8.8–15.4 months). Patients with appendicular muscle mass of 19.0 kg or more (quartile four; highest muscle mass) had significantly longer overall survival...
Fig 1. Appendicular muscle mass in each subset was shown with a p-value of Wilcoxon rank-sum test. The median was presented as the black line. The top and bottom of each box indicated the upper and lower quartiles of the samples and the bars represented the minimum and maximum values. M, metastasis; PD, progressive disease.

https://doi.org/10.1371/journal.pone.0204985.g001

Fig 2. Association between appendicular muscle mass and hemoglobin level (a) and handgrip strength (b). The grey area indicates the 95% confidence interval.

https://doi.org/10.1371/journal.pone.0204985.g002

Table 3. Simple and multiple linear regression analysis using appendicular muscle mass as the dependent variable.

|                         | Simple linear regression | Multiple linear regression |
|-------------------------|--------------------------|----------------------------|
|                         | Coefficient 95% CI p-value | Coefficient 95% CI p-value |
| Age (years)             | -0.11 -0.19, -0.04 0.004* | -0.10 -0.16, -0.04 0.002*   |
| Female                  | -3.71 -5.11, -2.31 <0.001* | -3.96 -5.15, -2.76 <0.001*  |
| BMI (kg/m²)             | 0.28 0.09, 0.47 0.005*    | 0.23 0.09, 0.38 0.002*      |
| Hb (g/dL)               | 0.48 0.09, 0.87 0.016*    | 0.17 -0.12, 0.46 0.252      |
| Albumin (g/dL)          | 0.75 -0.54, 2.05 0.250    | -                           |
| Handgrip strength (kg)  | 0.13 0.06, 0.20 <0.001*   | 0.05 -0.01, 0.11 0.077      |
| Biliary drainage        | -1.50 -3.19, 0.19 0.081   | -                           |

Dependent variable, appendicular muscle mass; Adjusted R² = 0.569; the level of significance at p < 0.05; CI, confidence interval; BMI, body mass index; Hb, hemoglobin

https://doi.org/10.1371/journal.pone.0204985.t003
compared with those with low muscle mass (quartiles 1–3) with a hazard ratio (HR) of 0.46 (95% CI 0.22–0.95, p = 0.037) (Fig 3).

BMI was not significantly associated with overall survival; however, obese patients were at highest risk for poor survival outcome. The median survival for underweight, normal-weight, overweight, and obese patients were 10.7, 13.9, 9.7, and 3.3 months respectively (p = 0.06).

In the final survival model, two independent variables including neutrophil-lymphocyte ratio (NLR) and high appendicular muscle mass were significant predictors of OS (Table 4). The adjusted hazard ratios (95% confidence interval) of these two factors were 1.17 (1.01, 1.35)

![Graph](https://doi.org/10.1371/journal.pone.0204985.g003)

Fig 3. Patients with appendicular muscle mass of ≥ 19.0 kg (quartile four, highest amount of muscle mass) had a significantly longer overall survival compared with those with low appendicular muscle (quartiles one to three); HR 0.46, 95% CI 0.22–0.95, p = 0.037.

### Table 4. Univariable and multivariable Cox proportional hazards models for overall survival.

|                         | Univariable |           |           | Multivariable |           |           |
|-------------------------|-------------|-----------|-----------|---------------|-----------|-----------|
|                         | HR          | 95% CI    | p-value   | HR            | 95% CI    | p-value   |
| Appendicular muscle     |             |           |           |               |           |           |
| Quartile 1–3            | Ref         | Ref       | Ref       | Ref           | Ref       | Ref       |
| Quartile 4              | 0.46        | 0.22, 0.95| 0.037     | 0.40          | 0.18, 0.88| 0.023     |
| NLR                     | 1.26        | 1.11, 1.42| <0.001    | 1.17          | 1.01, 1.35| 0.039     |
| Chemotherapy            |             |           |           |               |           |           |
| Carboplatin-based       | Ref         | Ref       | Ref       | Ref           | Ref       | Ref       |
| Cisplatin-based         | 0.50        | 0.28, 0.89| 0.021     | 0.69          | 0.35, 1.36| 0.280     |
| Age (years)             | 0.99        | 0.96, 1.03| 0.607     | 0.97          | 0.94, 1.01| 0.185     |

HR, Hazard ratio; CI, confidence interval; NLR, neutrophil-lymphocyte ratio

https://doi.org/10.1371/journal.pone.0204985.t004

https://doi.org/10.1371/journal.pone.0204985.g003

https://doi.org/10.1371/journal.pone.0204985.003

https://doi.org/10.1371/journal.pone.0204985.t004
and 0.40 (0.18, 0.88), respectively. There was no significant violation of the proportional hazards assumption.

**Discussion**

To our knowledge, this is one of the first studies exploring the relationship between body composition and survival in biliary tract cancer. We noted several findings of interest. First, in this cohort, sarcopenia at diagnosis was 61.3% and skeletal muscle mass depletion at diagnosis predicted worse survival for advanced biliary tract cancer patients.

Sarcopenia was observed in more than half of the patients (69% of male patients and 35.3% of female patients; Table 2). It was comparable to previous reports for advanced stage cancers including esophageal, pancreatic, renal cell and urothelial carcinoma [13–16]. However, it is much higher than those reported in colorectal cancer [17, 18]. Tumor biology and natural history of disease differed. Colon cancer, even in advanced stage, the prognosis is fair with multiple options of treatment including multi-chemotherapy and targeted therapy.

We showed that low appendicular muscle mass was independently associated with increased all-cause mortality. Patients with BTC with the highest muscle mass (highest quartile) were at a significantly increased survival on multivariable analysis (HR 0.40; 95% CI, 0.18 to 0.88). The survival curve split early in the course, thereby highlighting the value of muscle mass as a baseline prognostic factor before chemotherapy. The results are in line with those reported in various malignancies, where low muscle mass was independently associated with reduced survival [11, 14, 19].

The hypotheses of sarcopenia as a risk of poor survival include inflammation, low immune activity, and inactivity. However, the mechanisms remain uncertain why it increases the risk of mortality. Neutrophil-lymphocyte ratio (NLR) was also the independent predictor for survival outcomes. There is increasing evidence indicates that inflammatory marker, particularly NLR, is a useful biomarker for recurrence and all-cause mortality [20, 21]. The meta-analysis of a total of 2093 patients with cholangiocarcinoma indicated that patients with high NLR had unfavorable OS outcomes [22]. Nevertheless, we did not find association between NLR and muscle depletion or sarcopenia in this cohort.

Aging is the most important physiological factor for muscle wasting leading to poor physical performance and frailty. In our cohort, we found that advanced age was correlated with decreased lean muscle mass, for each 1-year age increase, appendicular muscle mass decreased 0.10 kg. Since the incidence of elderly cancer is increasing [23, 24], evaluation of muscle mass along with geriatric assessment in elderly patients receiving chemotherapy is warranted. Female gender was also a risk for decreased muscle mass. Even though female patients had greater BMI compared to male patients, the muscle mass was significantly lower, but the fat mass was higher. Both ageing and gender were important factors determining the muscle mass but both factors were not associated with survival. In this cohort, the muscle mass was evaluated before the start of chemotherapy. The drug thus could not affect the loss of mass.

In this study, we assessed hemoglobin level before chemotherapy and found that it was positively correlated with appendicular muscle mass. The results were consistent with those reported from a study of 909 participants 65 years and older, which found that hemoglobin levels were significantly associated with muscle density and muscle area (measured by computed tomography) [25]. This may have been related to the nutritional status, coexistent of anemia of chronic disease, and frailty. Similarly, the functional assessment of grip strength was also associated with appendicular muscle mass. Because skeletal muscle has been linked to nutritional status, the plasma albumin level was quantified before chemotherapy, but we did not find any significant differences between the low- and high-muscle groups. A meta-analysis...
which included 2125 individuals demonstrated that even in the context which malnutrition was obviously observed, the serum albumin levels were normal[26]. Hence, the role of albumin as a measure of nutritional status might be weak but could be used as a complement to other clinical factors.

BMI was significantly associated with skeletal muscle mass and there was a trend toward survival outcome. Survival was better in the normal-weight group, while obese patients had the shortest overall survival. The findings were consistent with previous studies of both biliary tract cancer and other cancer types [27–28]. The obesity paradox pattern of survival that was mentioned by Lennon et al [29] was also demonstrated.

The strength of this study was that muscle mass was measured by DXA scan which evaluated the whole skeletal muscle and data regarding muscle function was assessed prospectively. We defined sarcopenia according to the international consensus definitions by AWGS, which are sex- and race- specific for Asian people and include both the muscle mass and muscle strength; the handgrip strength and overall performance by measuring gait speed [9]. However, it is noteworthy to mention that the lumbar skeletal muscle index at L3 from computed tomography is still the widely used method to measure sarcopenia and has been validated in various cancers [11, 15, 19]. It is a convenient and could be obtained simultaneously with the imaging for biliary tract cancer.

Interestingly, the rate of sarcopenia was high even though we included only patients with ECOG performance status of 0 or 1. This leads us to conclude that the general health conditions in cholangiocarcinoma patients are poor and sarcopenia could be occult.

The main limitation is the relatively small sample size, particularly in subgroup analysis. The cross-sectional design of our study cannot explain the change of muscle mass after chemotherapy. Further longitudinal studies are warranted to evaluate the chemotherapy effect to muscle mass and its effect to survival.

**Conclusion**

Sarcopenia was common in BTC even in good performance status patients. Low muscle mass was associated with advanced age, female gender, and low BMI and it was an independent prognostic factor for survival. Since there is no molecular biomarker that predict outcome of chemotherapy, body composition should be considered as a potential marker. As such, we propose that interventions to modify skeletal muscle wasting may result in better outcome before and during chemotherapy.

**Supporting information**

S1 Table. Clinical characteristics of 75 biliary tract cancer patients. (XLS)

**Author Contributions**

**Conceptualization:** Panita Limpawattana, Daris Theerakulpisut, Aumkhae Sookprasert, Narong Khuntikeo, Jarin Chindaprasirt.

**Data curation:** Panita Limpawattana, Daris Theerakulpisut, Jarin Chindaprasirt.

**Formal analysis:** Daris Theerakulpisut, Narong Khuntikeo, Jarin Chindaprasirt.

**Funding acquisition:** Aumkhae Sookprasert, Jarin Chindaprasirt.

**Investigation:** Daris Theerakulpisut, Kosin Wirasorn, Aumkhae Sookprasert.
Methodology: Panita Limpawattana, Daris Theerakulpisut, Kosin Wirasorn, Aumkhae Sookprasert, Jarin Chindaprasirt.

Project administration: Jarin Chindaprasirt.

Resources: Daris Theerakulpisut, Jarin Chindaprasirt.

Supervision: Panita Limpawattana, Kosin Wirasorn, Aumkhae Sookprasert, Narong Khuntikeo, Jarin Chindaprasirt.

Validation: Daris Theerakulpisut, Narong Khuntikeo, Jarin Chindaprasirt.

Visualization: Aumkhae Sookprasert, Jarin Chindaprasirt.

Writing – original draft: Panita Limpawattana, Jarin Chindaprasirt.

Writing – review & editing: Panita Limpawattana, Daris Theerakulpisut, Kosin Wirasorn, Aumkhae Sookprasert, Narong Khuntikeo, Jarin Chindaprasirt.

References

1. Wirasorn K, Suwannunruag K, Wiangnon S, Punjaruk W. Numbers of new cases and trends of cancer 1993–2012: Sirnagarind hospital based population, Khon Kaen, North-East Thailand. Asian Pac J Cancer Prev. 2014; 15(19):8423–7. PMID: 25339040.

2. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261–80. PMID: 27095655.

3. Khuntikeo N, Chamadol N, Yongvanit P, Naphon S, Punjaruk W, et al. Cohort profile: cholangiocarcinoma screening and care program (CASCAP). BMC Cancer. 2015; 15:459. https://doi.org/10.1186/s12885-015-1475-7 PMID: 26054405.

4. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007; 96(6):896–902. https://doi.org/10.1038/sj.bjc.6603648 PMID: 17325704.

5. Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014; 25(2):391–8. https://doi.org/10.1093/annonc/mdt540 PMID: 24351397.

6. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. New England Journal of Medicine. 2010; 362(14):1273–81. https://doi.org/10.1056/NEJMoa0908721 PMID: 20375404.

7. Kelly CM, Shahrokni A. Moving beyond Karnofsky and ECOG Performance Status Assessments with New Technologies. J Oncol. 2016; 2016:6186543. https://doi.org/10.1155/2016/6186543 PMID: 27068075.

8. Leal AD, Allmer C, Maurer MJ, Shanafelt TD, Cerhian JR, Link BK, et al. Variability of performance status assessment between patients with hematologic malignancies and their physicians. Leuk Lymphoma. 2018; 59(3):695–701. https://doi.org/10.1080/10428194.2017.1347930 PMID: 28718335.

9. Chen LK, Liu LK, Wu J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. Journal of the American Medical Directors Association. 2014; 15(2):95–101. https://doi.org/10.1016/j.jamda.2013.11.025 PMID: 24461239.

10. Chindaprasirt J. Sarcopenia in Cancer Patients. Asian Pac J Cancer Prev. 2015; 16(18):8075–7. PMID: 26745041.

11. Choi Y, Oh DY, Kim TY, Lee KH, Han SW, Im SA, et al. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. PloS One. 2015; 10(10):e0139749. https://doi.org/10.1371/journal.pone.0139749 PMID: 26437072.

12. Ninomiya G, Fujii T, Yamada S, Yabuaki N, Suzuki K, Iwata N, et al. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study. Int J Surg. 2017; 39:45–51. https://doi.org/10.1016/j.ijsu.2017.01.075 PMID: 28110029.

13. Pautka SP, Carrasco A, Schmit GD, Moynagh MR, Boorjian SA, Frank I, et al. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer. 2014; 120(18):2910–8. https://doi.org/10.1002/cncr.28796 PMID: 24840865.
14. Dalal S, Hui D, Bidaut L, Lem K, Del Fabbro E, Crane C, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manage. 2012; 44(2):181–91. https://doi.org/10.1016/j.jpainsymman.2011.09.010 PMID: 22695045
15. Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F. Prognostic Significance of Sarcopenia in Patients with Metastatic Renal Cell Carcinoma. J Urol. 2016; 195(1):26–32. https://doi.org/10.1016/j.juro.2015.08.071 PMID: 26292042.
16. Tamandl D, Paireder M, Asari R, Baltzer PA, Schoppmann SF, Ba-Ssalamah A. Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer. Eur Radiol. 2016; 26(5):1359–67. https://doi.org/10.1007/s00330-015-3963-1 PMID: 26334504.
17. Thoresen L, Frykholm G, Lydersen S, Ulveland H, Baracos V, Birdsell L, et al. The association of nutritional assessment criteria with health-related quality of life in patients with advanced colorectal cancer. Eur J Cancer Care (Engl). 2012; 21(4):505–16. https://doi.org/10.1111/j.1365-2354.2012.01327.x PMID: 22309292.
18. van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg. 2012; 99(4):550–7. https://doi.org/10.1002/bjs.7283 PMID: 22246799.
19. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer. 2016; 57:58–67. https://doi.org/10.1016/j.ejca.2015.12.030 PMID: 26882087.
20. Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017; 19(1):2. https://doi.org/10.1186/s13058-016-0794-1 PMID: 28057046
21. Ma J, Kuzman J, Ray A, Lawson BO, Khong B, Xuan S, et al. Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma. Sci Rep. 2018; 8(1):4044. https://doi.org/10.1038/s41598-018-22425-3 PMID: 29511262
22. Xue TC, Zhang L, Xie XY, Ge NL, Li LX, Zhang BH, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis. PLoS One. 2014; 9(5):e96072. https://doi.org/10.1371/journal.pone.0096072 PMID: 24788770
23. Wirasorn K, Suwanrugruang K, Sookprasert A, Limpawattana P, Sirithanaphol W, Chindaprasirt J. Hospital-based Population of Elderly Cancer Cases in Northeastern Thailand. Asian Pac J Cancer Prev. 2016; 17(2):767–70. PMID: 26925677.
24. Marosi C, Koller M. Challenge of cancer in the elderly. ESMO Open. 2016; 1(3):e000020. https://doi.org/10.1136/esmoopen-2015-000020 PMID: 27643603
25. Cesari M, Penninx BW, Lauretani F, Russo CR, Carter C, Bandinelli S, et al. Hemoglobin levels and skeletal muscle: results from the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004; 59(3):249–54. PMID: 15031309.
26. Lee JL, Oh ES, Lee RW, Finucane TE. Serum Albumin and Prealbumin in Calorically Restricted, Nondiseased Individuals: A Systematic Review. Am J Med. 2015; 128(9):1023 e1–22. https://doi.org/10.1016/j.amjmed.2015.03.032 PMID: 25912205.
27. Kang J, Lee SH, Son JH, Lee JW, Choi YH, Choi JH, et al. Body mass index and weight change during initial period of chemotherapy affect survival outcome in advanced biliary tract cancer patients. PLoS One. 2018; 13(4):e0195118. https://doi.org/10.1371/journal.pone.0195118 PMID: 29608578
28. Martin L, Senesse P, Gioubasianis I, Antoun S, Bozetti F, Deans C, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015; 33(1):90–9. https://doi.org/10.1200/JCO.2014.56.1894 PMID: 25422490
29. Lennon H, Sperrin M, Badrick M, Renehan AG. The Obesity Paradox in Cancer: a Review. Curr Oncol Rep. 2016; 18(9):56. https://doi.org/10.1007/s11912-016-0539-4 PMID: 27475805